Study Group: BiDil Prescribers (US)(?)
Council Members in this Study Group: 58
Request a survey with this Study Group
Leading Experts in this Study Group
Clinical Director
NYU Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...
Hossein Ardehali, MD, PhDAssistant Professor
Feinberg School of Medicine, Northwestern University
Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...
Cardiologist
NYU Medical Center
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...
Owner
Joshua M. Feuer, MD
Joshua Feuer, MD, FACC, is a board certified Cardiologist in private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment, and reduction. He has...
Inder Anand, MD, FACC, FRCP, DPhilDirector of the Heart Failure Program
Minneapolis VA Medical Center
Inder Anand, MD, FACC, FRCP, DPhil, is Professor of Medicine at the University of Minnesota. Dr. Anand is also Director of the Heart Failure Program at the Minneapolis VA Medical Center. Dr. Anand has expertise in pathophysiology and management of heart failure. He has been a principal investigator...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent. It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
TRITON-TIMI 38 study of 13,608 patients with ACS compared prasugrel against clopidogrel, combined with aspirin. Prasugrel reduced the combined rate of CV death, MI or stroke (12.1% for clopidogrel vs. 9.9% for prasugrel). The benefit came at a cost of increased serious bleeding (1.4%, vs....
Physicians have several possible conclusions that can be taken; These include: - the trial is flawed - the selection of patients with much less CIMT than previous trials such as ASAP and ARBITER flaws the study - the failure to meet the trial endpoint is only a surrogate and clinical trial data...
This is great news for Canada. This is the first new drug approved for the treatment of acute heart failure since 1989, when milrinone was approved. Nesiritide was approved in the United States in 2001. Since then, it has proven to be of great benefit in patients with acute heart failure,...
By restoring function in the late Na channel and hence improving diastolic function (amongst other things), Ranexa has worked terrifically in my patients with any evidence for diastolic dysfunction. This typically manifests with shortness of breath and can be associated with an elevated level...
Most Common Company Types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Academic Institution*
- Other Freestanding Healthcare Facility
- Government/Military Hospital or Clinic
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- Partner
- Physician - Division Head
- Professor
- Medical Director
- President
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms